DamianJonathanGreenMD

PubMed

• Development and validation of predictive models of early immune effector cell-associated hematotoxicity (eIPMs).
  Emily C Liang, Jennifer J Huang, Andrew J Portuguese, Valentín Ortiz-Maldonado, Aya Albittar
  Blood Advances. 2024-12-03
• Kinetics of Nirogacestat-Mediated Increases in B-cell Maturation Antigen on Plasma Cells Inform Therapeutic Combinations in Multiple Myeloma.
  Todd Shearer, Melissa Comstock, Rex L Williams Jr, Mark C Johnson, Ewa Cendrowicz
  Cancer Research Communications. 2024-12-01
• Modified poly-L-lysine for use as a clearing agent in pretargeted radioimmunotherapy.
  Chiara Timperanza, Anna Gustafsson-Lutz, Tom Bäck, Damian J Green, Sture Lindegren
  EJNMMI Radiopharmacy and Chemistry. 2024-11-13

Journal Articles

• Long Term Follow-up of Tandem Autologous-Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma  
  Parameswaran Hari, Brenda M Sandmaier, Pamela S Becker, Leona Holmberg, Damian J Green, Peter A McSweeney, David G Maloney, Thomas R Chauncey, Haematologica

Abstracts/Posters

• Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Re...
  Damian J. Green, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Reduced Antigen Presentation May Contribute to Immunomodulatory Drug Resistance in Multiple Myeloma
  Damian J. Green, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
  Damian J. Green, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• High-Throughput Functional Drug Screening and Genomic Analysis to Guide Individualized Therapy for Relapsed/Refractory Multiple Myeloma
  Damian J. Green, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Response to Bcma CAR-T Cells Correlates with Pretreatment Target Antigen Density and Is Improved By Small Molecule Inhibition of Gamma Secretase 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• The Alpha Emitter Astatine-211 Targeted to CD38 Can Eradicate Multiple Myeloma in Minimal Residual Disease Models 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Prolonged Lenalidomide Therapy in Multiple Myeloma Patients Does Not Impact Autologous PBSC Mobilization: A Single Center Retrospective Analysis 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018